Breaking the Biofilm Barrier: Natural Products, Advanced Therapies, and Emerging Strategies Against Streptococcus mutans–Candida Polymicrobial Oral Biofilms
Microbial Bioactives · 01.01.2026 · 9 (1) · 1-8
DOI: 10.25163/microbbioacts.9110606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Bioactives, online erschienen am 01.01.2026. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The global escalation of antimicrobial resistance (AMR) has significantly undermined the effectiveness of conventional antimicrobial therapies, necessitating urgent exploration of alternative treatment strategies. Oral biofilm–associated infections, particularly those driven by polymicrobial consortia of Streptococcus mutans and Candida species, represent a major clinical challenge due to their heightened virulence, metabolic cooperation, and intrinsic resistance to antimicrobial agents. These cross-kingdom biofilms are central to the pathogenesis of dental caries and periodontal disease, conditions that collectively affect billions of individuals worldwide and impose substantial economic and quality-of-life burdens. This systematic review and meta-analytical synthesis evaluates current evidence on novel therapeutic approaches targeting S. mutans–Candida oral biofilms, with a specific focus on natural products, antimicrobial peptides, nanotechnology-based delivery systems, quorum sensing inhibitors, and antimicrobial photodynamic therapy. Emphasis is placed on bioactive compounds derived from underexplored ecological niches, including marine, halophilic, and Antarctic microorganisms, which have demonstrated potent antibiofilm and antimicrobial activities in preclinical models. Using structured literature selection criteria, studies reporting quantitative efficacy metrics such as minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC), and IC50 values were analyzed to compare effect sizes across compound classes. The findings highlight that strategies disrupting extracellular polymeric substance (EPS) matrices, metabolic cooperation, and signaling pathways are consistently more effective than conventional monotherapies. Collectively, this review underscores the therapeutic potential of integrating natural product discovery with advanced biofilm-targeted technologies. It further identifies critical gaps in translational research, emphasizing the need for standardized in vivo models and clinical validation to advance promising antibiofilm agents toward clinical application.
Zitieren
APA
(2026). Breaking the Biofilm Barrier: Natural Products, Advanced Therapies, and Emerging Strategies Against Streptococcus mutans–Candida Polymicrobial Oral Biofilms. Microbial Bioactives, 9(1), 1-8. https://doi.org/10.25163/microbbioacts.9110606
Vancouver
Breaking the Biofilm Barrier: Natural Products, Advanced Therapies, and Emerging Strategies Against Streptococcus mutans–Candida Polymicrobial Oral Biofilms. Microbial Bioactives. 2026;9(1):1-8. doi:10.25163/microbbioacts.9110606
BibTeX
@article{euvimed2026,
title = {Breaking the Biofilm Barrier: Natural Products, Advanced Therapies, and Emerging Strategies Against Streptococcus mutans–Candida Polymicrobial Oral Biofilms},
journal = {Microbial Bioactives},
year = {2026},
volume = {9},
number = {1},
pages = {1--8},
doi = {10.25163/microbbioacts.9110606}
}
EUVIMED